DaVita Stock: Assessing After The Rally (NYSE:DVA)

DaVita headquarters in Denver, Colorado, USA

JHVEPhoto/iStock Editorial via Getty Images

DaVita (NYSE:DVA) has rallied over 40% after cratering on Ozempic related fears. Additional commentary that GLP-1s could erode DaVita’s business has been nonexistent since, proving once again Mr. Market can be quite an irrational fellow.


Rate this post

Leave a Comment